Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate

NCT00807963 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.

NCT NCT00807963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00807963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate
Lead sponsor
Halozyme Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
September 21, 2009
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

risk factors for or a diagnosis of osteoporosis